Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
18 studies found for:    "multiple endocrine neoplasia"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Active, not recruiting Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes
Condition: Multiple Endocrine Neoplasia
Intervention: Behavioral: Questionnaire
2 Completed Vancomycin Associated Red Man Syndrome (RMS)
Condition: Red Man Syndrome
Intervention:
3 Completed Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS)
Conditions: Muscle Rigidity;   Spasm;   Stiff Man Syndrome
Intervention: Drug: IVIg
4 Completed
Has Results
Treatment of Zollinger-Ellison Syndrome With Prevacid
Conditions: Zollinger-Ellison Syndrome;   Multiple Endocrine Neoplasia
Intervention: Drug: Lansoprazole (Prevacid)
5 Recruiting Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Multiple Endocrine Neoplasia Type 1;   Pancreatic Neuroendocrine Carcinoma
Interventions: Radiation: Computed Tomography Perfusion Imaging;   Other: Laboratory Biomarker Analysis;   Biological: Ziv-Aflibercept
6 Completed Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Conditions: Medullary Thyroid Carcinoma;   Multiple Endocrine Neoplasia Type 2
Intervention:
7 Active, not recruiting Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Conditions: Medullary Thyroid Carcinoma;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B
Intervention: Drug: Vandetanib
8 Recruiting Studies of Inherited Diseases of Metabolism
Conditions: Hypercalcemia;   Hyperparathyroidism;   Multiple Endocrine Neoplasia
Intervention:
9 Active, not recruiting Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
Conditions: Multiple Endocrine Neoplasia;   Recurrent Thyroid Gland Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Sorafenib Tosylate
10 Not yet recruiting Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment
Condition: Pancreatic Neuroendocrine Tumors in MEN1
Intervention: Drug: Somatostatin-Analog
11 Not yet recruiting Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Conditions: Functional Pancreatic Neuroendocrine Tumor;   Malignant Somatostatinoma;   Merkel Cell Carcinoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Carcinoid Tumor;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B;   Neuroendocrine Neoplasm;   Non-Functional Pancreatic Neuroendocrine Tumor;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Merkel Cell Carcinoma;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Adrenal Cortex Carcinoma;   Stage III Thyroid Gland Medullary Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IVA Thyroid Gland Medullary Carcinoma;   Stage IVB Thyroid Gland Medullary Carcinoma;   Stage IVC Thyroid Gland Medullary Carcinoma;   Thymic Carcinoid Tumor;   VIP-Producing Neuroendocrine Tumor;   Well Differentiated Adrenal Cortex Carcinoma;   Zollinger Ellison Syndrome
Interventions: Drug: Capecitabine;   Drug: Temozolomide;   Drug: Veliparib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
12 Completed High Dose Somatostatin Analogues in Neuroendocrine Tumors
Conditions: Respiratory Tract Neoplasms;   Thymic Neoplasms;   Pancreatic Neoplasms;   Gastrointestinal Neoplasms;   Multiple Endocrine Neoplasia
Intervention: Drug: Octreotide-LAR
13 Terminated A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors;   Adrenal Gland Tumors;   Neuroblastoma;   Pancreatic Neuroendocrine Tumors;   Multiple Endocrine Neoplasia
Interventions: Drug: pertuzumab;   Drug: erlotinib
14 Completed
Has Results
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
Conditions: Gastrin-Producing Neuroendocrine Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Multiple Endocrine Neoplasia Type 1;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Somatostatin-Producing Neuroendocrine Tumor
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study
15 Enrolling by invitation Genetic Evaluation of Families With Endocrine Cancers
Conditions: Pancreatic Cancer;   Thymic Cancer;   Parathyroid Disease;   MEN1 Syndrome
Intervention: Genetic: Blood draw
16 Recruiting Natural History Study of Children and Young Adults With Medullary Thyroid Cancer
Condition: Medullary Thyroid Carcer
Intervention:
17 Completed Cinacalcet to Treat Familial Primary Hyperparathyroidism
Conditions: Hypercalcemia;   Familial Primary Hyperparathyroidism
Interventions: Procedure: Parathyroid hormone testing;   Procedure: Serum calcium testing
18 Recruiting Diagnosis of Pheochromocytoma
Condition: Pheochromocytoma
Intervention:

Study has passed its completion date and status has not been verified in more than two years.